3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lung Neoplasms
3
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Leukemia, Myelomonocytic, Chronic
1
Gastrointestinal Neoplasms
1
Clonal Cytopenia of Undetermined Significance
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
74
Sunitinib
73
pembrolizumab
49
Everolimus
39
Sorafenib
36
Bevacizumab
36
Axitinib
36
cabozantinib
35
Radiosurgery
33
Ipilimumab
33
pazopanib
32
Magnetic Resonance Spectroscopy
27
Interleukin-2
27
aldesleukin
23
Specimen Handling
22
Cyclophosphamide
21
lenvatinib
20
fludarabine phosphate
17
Radiotherapy
16
Interferon-alpha
15
Peripheral Blood Stem Cell Transplantation
14
Gemcitabine
14
Biopsy
14
temsirolimus
13
Nephrectomy
13
durvalumab
11
Immunohistochemistry
11
CTLA-4 Antigen
11
Blood Specimen Collection
11
Capecitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Renal Cell
×
canakinumab
×
Clear all
NCT04028245
2026-04-15
SPARC-1
Columbia University
Phase EARLY_PHASE1
Completed
17 enrolled